Neuland Laboratories jumped 5.71% to Rs 6,400.65 after the firm said that its manufacturing facility located at Hyderabad has successfully completed the United States Food and Drug Administration (USFDA) inspection with zero observations.
The USFDA had conducted the inspection from 18 March 2024 to 22 March 2024 at company's unit 1 manufacturing facility at Bonthapally, Hyderabad.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and nternational markets.
The company reported a consolidated net profit of Rs 81.39 crore in Q3 FY24, steeply higher than Rs 30.55 crore posted in Q3 FY23. Net sales jumped 45.9% year on year to Rs 392.83 crore in Q3 FY23.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app